

North America Veterinary Pain Management Market - Industry Trends and Forecast to 2034

Market Report | 2023-09-01 | 150 pages | Data Bridge Market Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- Corporate Users License \$4200.00

Report description:

North America veterinary pain management market is expected to reach USD 1,256,306.51 thousand by 2030 from USD 728,148.69 thousand in 2022 growing at a CAGR of 7.2% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation

North America Veterinary Pain Management Market, By Product Type (Analgesics, Corticosteroids, and Alpha 2 Agonists), Drug Type (Branded and Generic), Mode of Purchase (Prescription Based and OTC), Animal Type (Companion Animal and Production Animal), Pain Source (Chronic Pain, Acute Pain, Post-Operative Pain, and Dental Pain), Dosage (Solid, Liquid, and Semi-Solid), Route of Administration (Parenteral, Oral, and Topical), End User (Veterinary Hospitals, Veterinary Clinics, Pet Shops, Animal Farms, Academic & Research Institutes, and Others), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2030 Overview of North America Veterinary Pain Management Market Dynamics

Driver

- Rising incidences of pet diseases

Restraint

- High costs of pet care

Opportunity

- Technological advancements for pain management

Market Players

Some of the major market players operating in the North America veterinary pain management market are:

- Dechra Pharmaceuticals PLC
- Virbac
- Norbrook
- Durvet Animal Health Products
- Bimeda, Inc.
- Inovet (A subsidiary of Orion Group)
- Chanelle Pharma
- Vetoquinol
- Elanco
- Merck & Co., Inc.
- Zoetis Services LLC
- Ceva Animal Health, LLC

Table of Contents:

TABLE OF CONTENTS **1 INTRODUCTION 17** 1.1 OBJECTIVES OF THE STUDY 17 **1.2 MARKET DEFINITION 17** 1.3 OVERVIEW OF THE NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET 17 1.4 CURRENCY AND PRICING 19 1.5 LIMITATIONS 19 1.6 MARKETS COVERED 20 2 MARKET SEGMENTATION 23 2.1 MARKETS COVERED 23 2.2 GEOGRAPHICAL SCOPE 24 2.3 YEARS CONSIDERED FOR THE STUDY 25 2.4 DBMR TRIPOD DATA VALIDATION MODEL 26 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29 2.6 MULTIVARIATE MODELLING 30 2.7 MARKET END USER COVERAGE GRID 30 2.8 PRODUCT LIFELINE CURVE 31 2.9 DBMR MARKET POSITION GRID 32 2.10 VENDOR SHARE ANALYSIS 33 2.11 SECONDARY SOURCES 34 2.12 ASSUMPTIONS 34 **3 EXECUTIVE SUMMARY 35 4 PREMIUM INSIGHTS 38** 4.1 PESTEL ANALYSIS 39 4.2 PORTER'S FIVE FORCES 40 4.3 BRAND REVENUE ANALYSIS 41 **5 MARKET OVERVIEW 42**

5.1 DRIVERS 44 5.1.1 INCREASING PET OWNERSHIP 44 **5.1.2 ADVANCEMENTS IN VETERINARY MEDICINE 44** 5.1.3 GROWING INCIDENCES OF PET DISEASES 45 5.1.4 INCREASED GOVERNMENT PROJECTS TO ENHANCE ANIMAL CARE 45 5.2 RESTRAINTS 46 5.2.1 INCREASING PET CARE COSTS 46 5.2.2 STRICT REGULATORY GUIDELINES 46? **5.3 OPPORTUNITIES 47** 5.3.1 RISING R&D ACTIVITIES AND PRODUCT APPROVAL FOR VETERINARY PAIN MANAGEMENT 47 5.3.2 RISING POPULARITY OF NON- CONVENTIONAL TREATMENT APPROACHES 48 5.3.3 TECHNOLOGICAL ADVANCEMENTS 48 5.4 CHALLENGES 49 5.4.1 LIMITED AVAILABILITY OF VETERINARIANS 49 5.4.2 RESISTANCE TO MEDICATIONS 49 6 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PRODUCT TYPE 50 6.1 OVERVIEW 51 6.2 ANALGESICS 52 6.2.1 ANTI- INFLAMMATORY (NSAIDS) 52 6.2.1.1 CARPROFEN 53 6.2.1.2 MELOXICAM 53 6.2.1.3 PHENYLBUTAZONE 53 6.2.1.4 ACETAMINOPHEN 53 6.2.1.5 FIROCOXIB 53 6.2.1.6 DERACOXIB 53 6.2.1.7 OTHERS 54 6.2.2 OPIOIDS 54 6.2.2.1 MU AGONISTS 54 6.2.2.1.1 METHADONE 55 6.2.2.1.2 MEPERIDINE 55 6.2.2.1.3 MORPHINE 55 6.2.2.1.4 OXYMORPHONE 55 6.2.2.1.5 OTHERS 55 6.2.2.2 PARTIAL MU AGONIST 55 6.2.2.2.1 BUPRENORPHINE 55 6.2.2.2.2 OTHERS 56 6.2.2.3 KAPPA AGONIST MU ANTAGONIST 56 6.2.2.3.1 BUTORPHANOL 56 6.2.2.3.2 OTHERS 56 6.3 CORTICOSTEROIDS 57 6.3.1 DEXAMETHASONE 57 6.3.2 PREDNISOLONE 57 6.3.3 PREDNISONE 57 6.3.4 OTHERS 58 6.4 ALPHA 2 AGONISTS 58? 7 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DRUG TYPE 59 **7.1 OVERVIEW 60**

7.2 BRANDED 61 7.3 GENERIC 61 8 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY MODE OF PURCHASE 62 **8.1 OVERVIEW 63** 8.2 PRESCRIPTION BASED 64 8.3 OTC 64 9 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ANIMAL TYPE 65 **9.1 OVERVIEW 66** 9.2 COMPANION ANIMAL 67 9.2.1 CANINE 68 9.2.2 EQUINE 68 9.2.3 FELINE 68 9.2.4 OTHERS 68 9.3 PRODUCTION ANIMAL 68 9.3.1 CATTLE 69 9.3.2 SWINE 69 9.3.3 POULTRY 69 9.3.4 FISH 69 9.3.5 OTHERS 69 10 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY PAIN SOURCE 70 10.1 OVERVIEW 71 10.2 CHRONIC PAIN 72 10.3 ACUTE PAIN 73 **10.4 POST OPERATIVE PAIN 73** 10.5 DENTAL PAIN 74 11 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY DOSAGE 75 **11.1 OVERVIEW 76** 11.2 SOLID 77 11.2.1 TABLET 77 11.2.2 POWDER 78 11.2.3 OTHERS 78? 11.3 LIQUID 78 11.3.1 SOLUTION 78 11.3.2 SYRUP 79 11.3.3 SUSPENSION 79 11.3.4 OTHERS 79 11.4 SEMI SOLID 79 11.4.1 GEL 80 11.4.2 CREAM 80 11.4.3 OTHERS 80 12 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY ROUTE OF ADMINISTRATION 81 12.1 OVERVIEW 82 12.2 PARENTERAL 83 12.3 ORAL 84 12.4 TOPICAL 84 13 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY END USER 85 13.1 OVERVIEW 86

13.2 VETERINARY HOSPITALS 87 13.3 VETERINARY CLINICS 88 13.4 PET SHOPS 88 13.5 ANIMAL FARMS 89 13.6 ACADEMIC & RESEARCH INSTITUTES 89 13.7 OTHERS 90 14 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, BY GEOGRAPHY 91 14.1 NORTH AMERICA 92 14.1.1 U.S. 100 14.1.2 CANADA 107 14.1.3 MEXICO 115 15 NORTH AMERICA VETERINARY PAIN MANAGEMENT MARKET, COMPANY LANDSCAPE 122 15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 122 16 SWOT ANALYSIS 123? **17 COMPANY PROFILE 124 17.1 ZOETIS SERVICES LLC 124** 17.1.1 COMPANY SNAPSHOT 124 **17.1.2 COMPANY SHARE ANALYSIS 124** 17.1.3 PRODUCT PORTFOLIO 125 **17.1.4 RECENT DEVELOPMENTS 125** 17.2 ELANCO 126 17.2.1 COMPANY SNAPSHOT 126 17.2.2 REVENUE ANALYSIS 126 17.2.3 COMPANY SHARE ANALYSIS 127 17.2.4 PRODUCT PORTFOLIO 127 17.2.5 RECENT DEVELOPMENT 127 17.3 MERCK & CO., INC. 128 17.3.1 COMPANY SNAPSHOT 128 17.3.2 REVENUE ANALYSIS 128 17.3.3 COMPANY SHARE ANALYSIS 129 17.3.4 PRODUCT PORTFOLIO 129 17.3.5 RECENT DEVELOPMENT 129 **17.4 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 130** 17.4.1 COMPANY SNAPSHOT 130 17.4.2 COMPANY SHARE ANALYSIS 130 17.4.3 PRODUCT PORTFOLIO 131 **17.4.4 RECENT DEVELOPMENT 131** 17.5 VETOQUINOL 132 17.5.1 COMPANY SNAPSHOT 132 17.5.2 REVENUE ANALYSIS 132 17.5.3 COMPANY SHARE ANALYSIS 133 17.5.4 PRODUCT PORTFOLIO 133 **17.5.5 RECENT DEVELOPMENTS 133** 17.6 BIMEDA, INC. 135 17.6.1 COMPANY SNAPSHOT 135 17.6.2 PRODUCT PORTFOLIO 135 **17.6.3 RECENT DEVELOPMENT 135**

17.7 CEVA ANIMAL HEALTH, LLC 136 17.7.1 COMPANY SNAPSHOT 136 17.7.2 PRODUCT PORTFOLIO 136 17.7.3 RECENT DEVELOPMENT 136? 17.8 CHANELLE PHARMA 137 17.8.1 COMPANY SNAPSHOT 137 17.8.2 PRODUCT PORTFOLIO 137 17.8.3 RECENT DEVELOPMENT 137 **17.9 DECHRA PHARMACEUTICALS PLC 138** 17.9.1 COMPANY SNAPSHOT 138 17.9.2 REVENUE ANALYSIS 138 17.9.3 PRODUCT PORTFOLIO 139 **17.9.4 RECENT DEVELOPMENTS 139** 17.10 DURVET ANIMAL HEALTH PRODUCTS 140 17.10.1 COMPANY SNAPSHOT 140 17.10.2 PRODUCT PORTFOLIO 140 17.10.3 RECENT DEVELOPMENT 140 17.11 INOVET (A SUBSIDIARY OF ORION GROUP) 141 17.11.1 COMPANY SNAPSHOT 141 17.11.2 PRODUCT PORTFOLIO 141 17.11.3 RECENT DEVELOPMENTS 141 17.12 NORBROOK 143 17.12.1 COMPANY SNAPSHOT 143 17.12.2 PRODUCT PORTFOLIO 143 17.12.3 RECENT DEVELOPMENT 143 17.13 VIRBAC 144 17.13.1 COMPANY SNAPSHOT 144 17.13.2 REVENUE ANALYSIS 144 17.13.3 PRODUCT PORTFOLIO 145 17.13.4 RECENT DEVELOPMENT 145 **18 QUESTIONNAIRE 146 19 RELATED REPORTS 150**



North America Veterinary Pain Management Market - Industry Trends and Forecast to 2034

Market Report | 2023-09-01 | 150 pages | Data Bridge Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$3500.00
	Corporate Users License	\$4200.00
	VAT	
	Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-05-07
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com